塔莱特雷克提尼布:首次获得批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand. dru@adis.com.
Drugs
|November 12, 2025
概括
塔莱特雷克提尼布是一种新的口服药物,用于ROS1阳性非小细胞肺癌. 它已在中国,美国和日本获得初步批准,用于晚期疾病的成年患者.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 药物开发 药物开发
背景情况:
- 具有ROS1变异的非小细胞肺癌 (NSCLC) 代表了重要的未满足需求.
- 针对性治疗对于改善晚期NSCLC的结果至关重要.
- 原瘤基因氨酸蛋白激酶-1 (c-Ros瘤基因-1;ROS1) 抑制剂提供了一个有前途的治疗策略.
研究的目的:
- 为了总结taletrectinib的发展里程碑.
- 突出在全球主要市场上对taletrectinib的监管批准.
- 为提供taletrectinib进入市场的路径的概述.
主要方法:
- 对临床开发数据的审查.
- 对监管提交时间表的分析.
- 关键的疗效和安全性发现的摘要,导致批准.
主要成果:
- 下一代ROS1抑制剂taletrectinib已在中国,美国和日本获得监管批准.
- 批准覆盖了局部晚期或转移性ROS1阳性NSCLC的成年患者,包括之前接受过ROS1抑制剂治疗的患者.
- 全球提交正在进行中,这表明持续的发展和潜在的更广泛的可访问性.
结论:
- 塔莱特雷克提尼布在治疗ROS1阳性NSCLC方面取得了重大进展.
- 药物的开发途径证明了从发现到监管批准的成功进展.
- 持续的全球申请表明,我们致力于扩大全球NSCLC患者的治疗选择.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
411
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
411
The Retinoblastoma Gene
4.6K
Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
4.6K
FDA Approved Drugs: Changes to Approved Drugs
214
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
214
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
414
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
414
Inhibition of Cdk Activity
5.5K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K


